Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TCR2 THERAPEUTICS INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

10/20/2021 | 08:18am EST

Item 7.01 Regulation FD Disclosure.

On October 20, 2021, TCR2 Therapeutics Inc. (the "Company") issued a press release titled "TCR2 Therapeutics Reviews Pipeline and Strategy at R&D Day." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information under this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished herewith and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The Company from time to time presents and/or distributes to the investment community slide presentations to provide updates and summaries of its business. On October 20, 2021, the Company hosted a virtual R&D Day with a conference call and webcast to discuss new programs and provide highlights from its emerging TRuC pipeline programs. A copy of its "Engaging the TCR to Transform the Treatment of Solid Tumors" slide presentation is being filed herewith as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

Statements contained under this Item 8.01, including Exhibit 99.2, regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to: express or implied statements regarding TCR2's expectations for the Phase 1/2 clinical trial of gavo-cel; TCR2's expectations for the safety and efficacy of its product candidates and enhancements, including gavo-cel, TC-510 and TC-520, compared to current T-cell therapy approaches; TCR2'sexpectations regarding the timing of determining an RP2D for gavo-cel, TCR2's expectations regarding the timing of INDs, TCR2's expectations regarding the estimated patient populations and related market opportunities in gavo-cel's, TC-510's and TC-520's targeted indications; TCR2's expectations regarding manufacturing of its product candidates, and TCR2's expectations regarding its product candidate pipeline and business development opportunities.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of a trial; the possibility that positive results from preclinical studies and correlative studies may not necessarily be predictive of the results of TCR2's planned clinical trials, including the Phase 1/2 clinical trial of gavo-cel; the risk that the results from the Phase 1/2 clinical trial of gavo-cel will not support further development and marketing approval; the risk that TCR2 may be unable to gain approval of gavo-cel and its other product candidates on a timely basis, if at all; the risk that TCR2 has over-estimated the potential patient population for its product candidates, if approved; the risk that the current COVID-19 pandemic will impact TCR2's clinical trials and other operations; and other risks set forth under the caption "Risk Factors" in TCR2's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. All forward-looking statements contained in this presentation speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits

Exhibit No.   Description

99.1            Press release issued by TCR2 Therapeutics Inc. on October 20,
99.2          Copy of TCR2 Therapeutics Inc. slide presentation dated October 20,
104           Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

11/22TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
11/11Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
11/10TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
11/10TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
11/10TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
11/10TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
11/01TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
11/01TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
11/01TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
11/01Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
More news
Analyst Recommendations on TCR2 THERAPEUTICS INC.
More recommendations